CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Off-Label Use of Intravenous Immunoglobulin for Autoimmune or Inflammatory Conditions: Clinical Effectiveness

Last updated: October 30, 2017
Project Number: RB1152-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical effectiveness of the off-label use of intravenous or subcutaneous immunoglobulin for the treatment of autoimmune or inflammatory conditions?

Key Message

Fourteen systematic reviews (three with meta-analyses), four randomized controlled trials, and seven non-randomized studies were identified regarding the clinical effectiveness of the off-label use of intravenous or subcutaneous immunoglobulin for the treatment of autoimmune or inflammatory conditions.